$28.52
0.66% yesterday
Nasdaq, Apr 03, 10:00 pm CET
ISIN
US4622221004
Symbol
IONS
Sector
Industry

Ionis Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Ionis Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
65%
Hold
31%
Sell
4%

Ionis Pharmaceuticals, Inc. Price Target

Target Price $57.14
Price $28.52
Potential
Number of Estimates 22
22 Analysts have issued a price target Ionis Pharmaceuticals, Inc. 2026 . The average Ionis Pharmaceuticals, Inc. target price is $57.14. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 26 analysts: 17 Analysts recommend Ionis Pharmaceuticals, Inc. to buy, 8 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Ionis Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Ionis Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 705.14 657.33
10.48% 6.78%
EBITDA Margin -64.26% -86.86%
52.80% 35.18%
Net Margin -68.08% -92.26%
32.65% 35.52%

20 Analysts have issued a sales forecast Ionis Pharmaceuticals, Inc. 2025 . The average Ionis Pharmaceuticals, Inc. sales estimate is

$657m
Unlock
. This is
6.84% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$801m 13.53%
Unlock
, the lowest is
$597m 15.36%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $705m 10.48%
2025
$657m 6.78%
Unlock
2026
$881m 34.04%
Unlock
2027
$1.2b 34.22%
Unlock
2028
$1.7b 43.85%
Unlock
2029
$2.3b 37.05%
Unlock

8 Analysts have issued an Ionis Pharmaceuticals, Inc. EBITDA forecast 2025. The average Ionis Pharmaceuticals, Inc. EBITDA estimate is

$-571m
Unlock
. This is
26.24% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-476m 5.17%
Unlock
, the lowest is
$-640m 41.47%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-453m 36.79%
2025
$-571m 26.01%
Unlock
2026
$-452m 20.82%
Unlock
2027
$-209m 53.67%
Unlock
2028
$162m 177.13%
Unlock

EBITDA Margin

2024 -64.26% 52.80%
2025
-86.86% 35.18%
Unlock
2026
-51.30% 40.94%
Unlock
2027
-17.71% 65.48%
Unlock
2028
9.49% 153.59%
Unlock

17 Ionis Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Ionis Pharmaceuticals, Inc. net profit estimate is

$-606m
Unlock
. This is
26.33% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-441m 8.22%
Unlock
, the lowest is
$-677m 41.12%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-480m 18.75%
2025
$-606m 26.33%
Unlock
2026
$-478m 21.25%
Unlock
2027
$-233m 51.12%
Unlock
2028
$77.9m 133.36%
Unlock
2029
$493m 533.49%
Unlock

Net Margin

2024 -68.08% 32.65%
2025
-92.26% 35.52%
Unlock
2026
-54.20% 41.25%
Unlock
2027
-19.74% 63.58%
Unlock
2028
4.58% 123.20%
Unlock
2029
21.16% 362.01%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -3.04 -3.84
18.75% 26.32%
P/E negative
EV/Sales 6.37

17 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast for earnings per share. The average Ionis Pharmaceuticals, Inc. EPS is

$-3.84
Unlock
. This is
26.32% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-2.79 8.22%
Unlock
, the lowest is
$-4.29 41.12%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-3.04 18.75%
2025
$-3.84 26.32%
Unlock
2026
$-3.02 21.35%
Unlock
2027
$-1.48 50.99%
Unlock
2028
$0.49 133.11%
Unlock
2029
$3.12 536.73%
Unlock

P/E ratio

Current -9.39 44.60%
2025
-7.43 20.87%
Unlock
2026
-9.43 26.92%
Unlock
2027
-19.29 104.56%
Unlock
2028
57.83 399.79%
Unlock
2029
9.13 84.21%
Unlock

Based on analysts' sales estimates for 2025, the Ionis Pharmaceuticals, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.94 21.32%
2025
6.37 7.30%
Unlock
2026
4.75 25.40%
Unlock
2027
3.54 25.50%
Unlock
2028
2.46 30.48%
Unlock
2029
1.80 27.04%
Unlock

P/S ratio

Current 6.43 19.85%
2025
6.90 7.34%
Unlock
2026
5.15 25.40%
Unlock
2027
3.83 25.50%
Unlock
2028
2.66 30.48%
Unlock
2029
1.94 27.04%
Unlock

Current Ionis Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Guggenheim
Locked
Locked
Locked Apr 03 2025
Redburn Atlantic
Locked
Locked
Locked Mar 31 2025
JP Morgan
Locked
Locked
Locked Mar 24 2025
JP Morgan
Locked
Locked
Locked Mar 11 2025
Needham
Locked
Locked
Locked Feb 20 2025
BMO Capital
Locked
Locked
Locked Feb 20 2025
RBC Capital
Locked
Locked
Locked Feb 20 2025
Analyst Rating Date
Locked
Guggenheim:
Locked
Locked
Apr 03 2025
Locked
Redburn Atlantic:
Locked
Locked
Mar 31 2025
Locked
JP Morgan:
Locked
Locked
Mar 24 2025
Locked
JP Morgan:
Locked
Locked
Mar 11 2025
Locked
Needham:
Locked
Locked
Feb 20 2025
Locked
BMO Capital:
Locked
Locked
Feb 20 2025
Locked
RBC Capital:
Locked
Locked
Feb 20 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today